Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T in R/R B-ALL
NCT05225831Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL19+22 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Senlang Bio. Primary endpoints: Incidence of adverse events up to 28 days and Remission Rate up to 3 months. Status: unknown.
02
Drugs
SL19+22 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05225831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225831.